At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 47 enrolled
Drug / intervention
Matched Sibling Allogeneic Transplantationdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Two Step Approach To Matched-Sibling Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematological Malignancies
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·interventional·Posted Mar 15, 2011·Updated Mar 19, 2026
In Brief
A Phase 2 clinical trial evaluating Matched Sibling Allogeneic Transplantation for Hematological Malignancies and 4 related conditions. Completed, enrolled 47 participants across 1 site.
Detailed Summary
This research study uses a drug called cyclophosphamide to decrease the incidence of GVHD in matched sibling hematopoietic stem cell transplant. In doing so, the goal of the study is to increase overall survival.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2008
First PostedMar 2011
Primary CompletionSep 2018
Study CompletionAug 2019
TodayJul 2026
First PostedMar 15, 2011
Enrollment StartApr 10, 2008
Primary CompletionSep 19, 2018
Study CompletionAug 29, 2019
TodayJul 2, 2026
Enrollment to primary: 10.4 yearsPosted 15.3 years ago
Interventions
Matched Sibling Allogeneic Transplantationdevice
Patients undergoing myeloablative hematopoietic stem cell transplant from HLA identical related donors using cyclophosphamide tolerization